VasoRx

About:

VasoRx is developing RNA therapies for diseases of the cardiovascular system & oncology such as atherosclerosis and pulmonary hypertension.

Website: https://vasrx.com/

Top Investors: Good Ventures

Description:

VasoRx is developing RNA therapies for diseases of the cardiovascular VasoRx is leading the translation of technologies discovered at Massachusetts Institute of Technology (M.I.T) and Yale for the delivery of RNAs for the treatment of diseases. With the world’s first approved RNAi therapeutic, the field of RNA medicines is rapidly expanding. VasoRx utilizes novel nanoparticles that are dramatically expanding the opportunities for developing RNA therapies for diseases of the cardiovascular system as well as oncology. system & oncology such as atherosclerosis and pulmonary hypertension.

Total Funding Amount:

$7.15M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Santa Barbara, California, United States

Founded Date:

2018-01-01

Founders:

Daniel Anderson, Krisztina Zsebo, Michael Simons, Robert Langer

Number of Employees:

1-10

Last Funding Date:

2020-11-01

IPO Status:

Private

Industries:

© 2025 bioDAO.ai